Establishment and Characterization of a Brca1^-/-, p53^-/- Mouse Mammary Tumor Cell Line.

ABSTRACT: Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. By the age of 80, the estimated risk for breast cancer for women with germline BRCA1 or BRCA2 mutations is around 80%. Genetically engineered BRCA1-deficient mouse models offer a unique opportunity to study the pathogenesis and therapy of triple negative breast cancer. Here we present a newly established Brca1^-/-, p53^-/- mouse mammary tumor cell line, designated as CST. CST shows prominent features of BRCA1-mutated triple-negative breast cancers including increased motility, high proliferation rate, genome instability and sensitivity to platinum chemotherapy and PARP inhibitors (olaparib, veliparib, rucaparib and talazoparib). Genomic instability of CST cells was co

SUBMITTER: Hamori L 

PROVIDER: S-EPMC7072850 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature